Natixis Advisors, L.P. Vertex Pharmaceuticals Inc Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 557,644 shares of VRTX stock, worth $262 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
557,644
Previous 461,886
20.73%
Holding current value
$262 Million
Previous $215 Million
4.54%
% of portfolio
0.42%
Previous 0.42%
Shares
30 transactions
Others Institutions Holding VRTX
# of Institutions
1,717Shares Held
222MCall Options Held
1.65MPut Options Held
1.37M-
Capital World Investors Los Angeles, CA26.8MShares$12.6 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.9 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.55 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.23 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $121B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...